greater than additive manner. While we did not detect an effect of MGF on CFU-G colony numbers stimulated by maximal concentrations of rhuG-CSF, MGF did enhance the size of CFU-G-derived colonies. MGF did not enhance the activity of rhuM-CSF. In a comparative assay, maximal concentrations of rmu and rhuMGF were equally effective in the enhancement of human bone marrow colony formation, but rhuMGF, in contrast t o rmuMGF, did not at the concentrations tested enhance colony formation by mouse bone marrow cells. MGF effects on BFU-E, CFU-GM, and CFU-GEMM may be direct acting ones as MGF-enhanced colony formation by these cells in highly enriched progenitor cell populations of CD34+++HLA-DR' and CD34+++HLA-DR'CD33-sorted cells in which 2 1 of 2 cells was a BFU-E plus CFU-GM plus CFU-GEMM. MGF appears to be an early acting cytokine that preferentially stimulates the growth of immature hematopoietic progenitor cells. Recently, a number of groups have isolated ligands for the c-kit receptor pr~tein.'~.~' The c-kit proto-oncogene, whose product has tyrosine kinase activity," is encoded by the "W' locus on murine chromosome 5.23,24 The c-kit receptor ligand appears to be a product of the murine steel ("SI") ~O C U S . '~~'~~~' ' These findings link up the abnormalities apparent in the genetically anemic W W and SI/Sld mice? which, respectively, have defects in stem cells and the hematopoietic microenvironment, among other disorders. 26 Ligands for the c-kit proto-oncogene product have been isolated as soluble molecules and called mast cell growth factor (MGF),''-15 stem cell factor (SCF),"." and KL'y,20 by the different groups. Membrane-bound forms have been reported.''^" The soluble ligands (in natural and recombinant forms) from m o~s e ' '~'~~~~ and ratl6,l7 have CFU-GMenhancing and erythroid (BFU-E) potentiating activity on mouse cells, and the rat and human (hu) formsI7 have activity on huBFU-E and huCFU-GM. It is not clear if these effects are direct on MPC and there is still a paucity of information on the activities of these molecules on hematopoietic cell proliferation, especially for human cells. Our current study evaluated the actions of the purified natural (n) and recombinant (r) forms of murine MGF on colony formation by normal human bone marrow CFU-GEMM, BFU-E, and CFU-GM, alone and in combination with rhuEpo, rhuIL-3, rhuGM-CSF, rhuG-CSF, and rhuM-CSF, and compared this to the effect of rhuMGF. Our results suggest that MGF is a potent growth factor that enhances/stimulates Epo-dependent CFU-GEMM and BFU-E. MGF activity on these cells is greater than that of IL-3 or GM-CSF, and at low concentrations of MGF, MGF synergises with optimal concentrations of IL-3 or GM-CSF to stimulate Epo-dependent CFU-GEMM and BFU-E. In addition, MGF also acts in combination with IL-3 and GM-CSF to greatly enhance the number and size of colonies derived from CFU-GEMM, BFU-E, and CFU-GM. In combination with G-CSF, MGF enhances the size of CFU-G colonies. MGF had no effect when placed in combination with M-CSF. Use of highly enriched human bone marrow progenitor cell populations (CD34'+'HLA-DR+, CD34"+HLA-DR+CD33-) with cloning efficiencies of 49% to 67% suggested that the MGF potentiating effects were directly on MPC.
MATERIALS AND METHODS

Cells.
Bone marrow cells were obtained from normal healthy donors who had given informed consent. Cells were separated by Ficoll-Hypaque (density, 1.077 gm/cm'; Pharmacia Fine Chemicals, Piscataway, NJ) into a low density (LD) fraction, or after adherence to plastic and removal of E-rosette-positive cells into a nonadherent LD T-lymphocytedepleted (NALDT-) fraction.' The NALDT-fraction had I 3% monocytes and T lymphocytes as determined by staining with nonspecific esterase and flow analysis with anti-CD3 antibodies.' NALDT-cells were further enriched for hematopoietic progenitor cells by fluorescence activated cell sorting using two-color ~taining',~ into a CD34+"HLA-DR+ population and using three-color staining into a CD34'++HLA-DR+CD33-population with a Coulter 753 Flow Cytometry System (Hialeah, FL). For three-color staining, cells were incubated with anti-CD34 (Becton Dickinson Immunocytometry Systems, San Jose, CA), followed by an isotype-specific Texas Red conjugated goat-antimouse IgG, antibody (Southern Biotechnology, Birmingham, AL). Mouse serum was added to block free binding sites for the second step reagent. Then fluorescein isothiocyanate (FITC)-conjugated anti-CD33 (Coulter Corp) and phycoerythrin-conjugated anti-HLA-DR were added (Becton Dickinson).2s Unseparated bone marrow from BDF, mice (Cumberland View Farms, Clinton, TN) were also used.
Natural MGF was isolated from a murine +I+ cell line" and purified as described." Units of MGF activity (amount required to stimulate half-maximal tritiated thymidine incorporation) were calculated using a murine MC-6 factor-dependent cell line proliferation assay.'' rmuMGF was expressed in yeast" and purified.'" rhuMGF was expressed and purified as I~U M G F . " , '~ rhuGM-CSF, rmuGM-CSF, and rhuIL-3 (each 10' Uimg as assessed by half-maximal tritiated thymidine incorporation into normal human or mouse bone marrow cell proliferation assays, respectively, for human or murine cytokines) were from Immunex Corporation (Seattle, WA). rhuM-CSF ( > 5 x lo7 U/mg) and rhuG-CSF (95% pure, >5 x lo7 U/mg), both assayed by mouse bone marrow colony formation, were kind gifts from Drs Peter Ralph and Robert Drummond (Cetus Corp, Emeryville, CA). Purified rhuEpo was purchased from Amgen Corp (Thousand Oaks, CA). Medium conditioned by the 5637 human urinary bladder carcinoma cell line (5637CM) was prepared as before." CSF activities of rhuGM-CSF, rhuIL-3, rhuM-CSF, rhuG-CSF, rhuEpo, and 5637CM have been Analysis of hematopoietic progenitor cells. LD, NALDT-, CD34"+HLA-DR', and CD34+"HLA-DR'CD33-cells were plated for CFU-GM assay in 0.4% agarose culture medium" or 0.3% agar culture medium,6 and for BFU-E and CFU-GEMM assay in 0.9% methylcellulose culture medium (except when sorted cells were plated and 1.3% methylcellulose was sed).'^^.^,^ Cells were incubated at 5% CO, in lowered (5%) 0,'2 and colonies scored after 12 to 14 days of incubation. Relative colony size was estimated by the area of the plate (in microns) occupied and the compact nature of the colony. Colony morphology in agarose was assessed in whole plates (100 colonies scored from each of three dishes per point) stained with a-naphthyl acetate esterase and lux01 fast blue and counterstained with hematoxylin.' CFU-GEMM
Cytokines.
colonies contained granulocytes, erythroid cells, monocytes/ macrophages, and, in most cases, megakaryocytes.
Three plates were scored for each CFU-GM point and four plates were scored for each BFU-E/CFU-GEMM sample. Results are expressed as the mean f 1 SEM. Levels of significance between samples were determined using Student's t distribution and greater than additive effects of cytokines were evaluated using x2 tests arising from a regression procedure assuming a Poisson distribution, with a modified Bonferroni procedure as previously described."
Statistics.
RESULTS
Influence of MGF on CFU-GEMM and BFU-E. nmuMGF and rmuMGF were evaluated in the absence and presence of rhuEpo, with or without rhuIL-3 or rhuGM-CSF, for effects on colony formation by normal human bone marrow CFU-GEMM and BFU-E. nmuMGF and rmuMGF were assayed, respectively, at 5, 20, and 50 U/mL and 5, 50, 100, and 200 ng/mL. When MGF was used in the absence of rhuEpo, no CFU-GEMM or BFU-E colonies formed. In the presence of rhuEpo, both the n and r preparations of muMGF had potent colony enhancing activity for CFU-GEMM (Fig 1) and BFU-E (Fig 2) . Maximal effects were obtained with 20 to 50 U/mL nmuMGF and 50 to 200 ng/mL rmuMGF and the results shown are for a low (n = 5 U/mL and r = 5 ng/mL) and plateau dose (n = 20 U/mL and r = 50 ng/mL) of MGF. The enhancing effects of MGF were apparent when LD BMC were used (Figs 1A and B and 2A and B), and also when NALDT-cells were used ( Figs 1C and 2C ). In the presence of plateau concentrations of MGF, threefold to fourfold and threefold to eightfold more CFU-GEMM colonies were formed, respectively, than with optimal concentrations (100 U/mL) of either rhuIL-3 or rhuGM-CSF (Fig 1) . BFU-E colonies were also stimulated in greater numbers with MGF than with IL-3 or GM-CSF (Fig 2) although the differences were not as great as for CFU-GEMM. In addition to effects on colony numbers, BFU-E colonies grown in the presence of 20 U/mL nmuMGF or 50 ng/mL rmuMGF were much larger in size than those stimulated with optimal concentrations of rhuEpo (1 U/mL) alone. Epo (1 U/mL)-dependent CFU-GEMM and BFU-E colonies grown in the presence of MGF were also larger by about twofold to fivefold than those stimulated in the presence of 100 U/mL rhuIL-3 or rhuGM-CSF. The potent enhancing activity of rmuMGF for Epo-stimulated BFU-E and CFU-GEMM has been noted using marrows from over 15 different normal donors. Representative results for five such experiments are shown in Table 1 .
When 5 U/mL nmuMGF or 5 ng/mL rmuMGF was added in combination with 100 U/mL rhuIL-3 or rhuGM-CSF (in the presence of 1 U/mL rhuEpo), the effects of MGF plus IL-3 or GM-CSF were additive or greater than additive for numbers of CFU-GEMM colonies (Fig 1) . The number of BFU-E with MGF plus GM-CSF or MGF plus IL-3 increased in a less than additive fashion although the number of BFU-E with either combination was greater than that seen with any factor alone (Fig 2) : When 20 U/mL nmuMGF or 50 ng/mL rmuMGF were used with 100 U/mL rhuIL-3 or rhuGM-CSF, the effects on numbers of CFU-GEMM and BFU-E were less than additive (Figs 1 and 2) . Influence of MGF, alone and plus CSF, on CFU-GM. nmuMGF (5 and 20 UlmL) and rmuMGF (5 and 50 ng/mL) were evaluated alone and in combination with either 10 or 100 U/mL rhuGM-CSF, 10 or 100 U/mL rhuG-CSF, or 100 or 1,000 U/mL rhuM-CSF, for effects on colony formation by normal human bone marrow CFU-GM (Fig 3) . nmuMGF and rmuMGF were able to stimulate some CFU-GM colonies ( > 90% contained both granulocytes and macrophages) when added to LD and NALDT-BMC. The size of MGF-stimulated colonies (slightly above 40 to 50 cells/ aggregate) was small compared with those stimulated by GM-CSF. The effects of MGF were more apparent when used in combination with other CSFs. MGF (n and r) had additive, or greater than additive, effects on colony numbers in the presence of 10 to 100 U/mL rhuGM-CSF, but not in the presence of 10 to 100 U/mL rhuG-CSF or 100 to 1,000 U/mL rhuM-CSF (Fig 3) . When used alone, 100 UimL rhuGM-CSF stimulated 16% 2 2% GM, 28% 5 2% G, 11% f 1% Eos, and 45% f 2% M colonies as assessed by histochemical staining of agarose cultures. The addition of 20 U/mL nmuMGF or 50 ng/mL rmuMGF with 100 U/mL rhuGM-CSF resulted in a fourfold increase in number of GM colonies and a twofold increase in number of G colonies with no change in the number of M colonies. The size of GM and G colonies grown in the presence of MGF plus rhuGM-CSF was about twofold to fourfold greater than those formed in the presence of either molecule alone. The synergistic effects of rmuMGFwith rhuGM-CSF has been seen in over 15 experiments, each using marrow from different normal donors. Five such representative experiments are seen in Table 1 . rhuG-CSF alone stimulated 77% 2 2% G colonies (Fig 3) and while the numbers of these colonies did not increase with MGF, the size of these colonies did increase by about twofold to fourfold. rhuM-CSF alone stimulated greater than 94% M colonies, but MGF did not appear to influence the number or size of M colonies stimulated with rhuM-CSF. In some cases, when LD BMC were used, MGF plus either rhuG-CSF or rhuM-CSF yielded a small increase in colony numbers, but this was always due to an increase in largesized GM colonies. When concentrations of 50 ng/mL rmu or rhuMGF were compared for activity on human bone marrow cells (Table 2) they were found to be equally active. Higher concentrations of each (up to 100 ng/mL) had no greater effect (data not shown). In contrast, while rmuMGF synergized with rmuGM-CSF to enhance mouse marrow CFU-GM colony formation, and synergized with Epo to enhance mouse BFU-E and CFU-GEMM colony formation, as reported elsewhere:' rhuMGF (50 ng/mL) did not stimulate or enhance the effects of rmuGM-CSF on mouse CFU-GM colony formation (27 f 1 and 27 3 colonies with 50 U/mL rmuGM-CSF without or with 50 ng rhuMGF per 7.5 X lo4 BDF, cells plated) or enhance the effect of Epo on mouse marrow BFU-E or CFU-GEMM (10 * 1 and 9 ? 1 BFU-E and 0 and 0 CFU-GEMM with 1 U Epo, respectively, without or with 50 ng rhuMGF per 7.5 x lo4 BDF, cells). Influence of MGF on highly enriched BFU-E and CFU-GM. To evaluate the effects of nmuMGF and rmuMGF on a population of cells more highly purified for hematopoietic progenitors than in the NALDT-fraction of cells, NALDT-cells were sorted into a CD34"'HLA-DR' population. The cumulative cloning efficiency for CFU-GM plus BFU-E when 125 cells were plated in the presence of 1 U/mL rhuEpo and 5% vol/vol5637CM was 49% ( Table 3 , part A). Both nmuMGF (20 U/mL) and rmuMGF (50 ng/mL) were able to significantly (P < .0001) increase colony numbers by BFU-E above the levels noted with Epo alone. CFU-GM numbers were also increased in the These assays were set up in 1.3% methylcellulose culture medium.
Comparative influences
*Significant increase compared with control medium, P < .01.
For personal use only. on November 10, 2017. by guest www.bloodjournal.org From presence of MGF using purified target cells. This enhancement in colony numbers was equal to or slightly greater than that seen with 200 WmL of either rhuIL-3 or rhuGM-CSF. It has been reported that a major subset of BFU-E expresses CD34 and HLA-DR, but not CD33, antigens.33 Thus, we also evaluated cytokine activity on CD34"'HLA-DR'CD33-cells using another normal human bone marrow (Table 3 , part B). rmuMGF plated in the presence of Epo enhanced colony formation by CFU-GM, BFU-E, and CFU-GEMM, resulting in a total cloning efficiency of 67%. In both experiments, the size of Epo-dependent BFU-E colonies stimulated by MGF was at least threefold to fourfold greater than that stimulated by IL-3 or GM-CSF, although the size of CFU-GM colonies was smaller than that stimulated by GM-CSF. The CFU-GEMM colonies forming in the presence of Epo plus MGF were as large as the similarly stimulated colonies seen in NALDT-cells.
DISCUSSION
A growing number of cytokines have been implicated in the complex network of biomolecule-cell interactions regulating blood cell production.'-'' These cytokines can stimulate, enhance, and/or suppress hematopoietic progenitor cell proliferation in vitro. Evidence for the in vivo action of a number of these cytokines is also available.% The variously named ligand(s) for the c-kit proto-~ncogene,'~-'~ can now be added to the list of early acting cytokines such as IL-3, GM-CSF,',26 IL-1,7,35"7 and IL-6.'2,37 In the present study we have confirmed, using n and r mouse MGF, the potent costimulating activity for human marrow BFU-E and CFU-GM noted by others" using rat and human SCF. Interestingly, maximal amounts of rmu and rhuMGF were equally active enhancing agents for human bone marrow colony formation (Table 2) , although when titered on a weight to weight basis the huMGF appears more active than rmuMGF on human cells (D.E. Williams, unpublished observations). The rhuMGF, when used at a concentration of 50 ng/mL, had no effect on mouse cells. Additionally, our results have produced the following new information. First, MGF is a potent stimulatindenhancing activity for CFU-GEMM from human marrow growth in the presence of Epo. A distinguishing feature of MGF is that it has much greater proliferative activity than maximal amounts of IL-3 or GM-CSF for Epo-dependent CFU-GEMM and BFU-E in terms of numbers and size of colonies stimulated. Second, while MGF by itself is a potent cofactor, at lowered concentrations and in combination with maximally acting concentrations of IL-3 or GM-CSF it has greater than additive activity on CFU-GEMM. Third, MGF does not appear to influence the growth of CFU-M colonies stimulated by rhuM-CSF. However, MGF is a potent costimulator of human marrow CFU-GM in terms of numbers and size of colonies formed in the presence of rhuGM-CSF, and MGF enhances the size, but not the numbers, of CFU-G colonies stimulated by plateau concentrations of rhuG-CSF. Others have noted that rhuSCF enhances rhuG-CSFstimulated colony number^.'^ Our inability to detect enhanced numbers of G-CSF-stimulated colonies with the rmuMGF used could be due to the species of MGF we used (we used muMGF for our studies), or possibly to the fact that we used plateau stimulating concentrations of rhuG-CSF. Fourth, the above effects were noted in the absence (using NALDT-cells) or presence (using LD cells) of T lymphocytes and monocytes, two known populations of accessory cells.' Fifth, MGF appears to be a direct acting cytokine at the level of responsive hematopoietic progenitor cells as suggested by its stimulatindenhancing activity for BFU-E, CFU-GM, and CFU-GEMM in the populations of NALDT-CD34++'HLA-DR+ and NALDT-CD34++'HLA-DR+CD33-cells in which greater than or equal to half of the cells were BFU-E, CFU-GM, and CFU-GEMM. Even in this highly purified population, the size of Epo-dependent BFU-E colonies growing in the presence of MGF was larger than that grown in the presence of IL-3 or GM-CSF and the size of Epodependent CFU-GEMM colonies was very large. This result suggests that MGF may be an earlier acting cytokine than IL-3 and GM-CSF, a possibility strengthened by the ability of MGF to enhance the number and proliferative capacity of CFU-GEMM, BFU-E, and CFU-GM responding to IL-3 or GM-CSF. MGF has no detectable activity on CFU-GEMM or BFU-E in the absence of Epo, and its activity for CFU-GM is minimal in terms of size and number of colonies stimulated compared with GM-CSF. Thus, a main function of MGF may be to enhance the proliferative capacity of progenitor cells responding to other cytokines. The MGF used in the present studies was a soluble form, but analysis of the structure of the MGF protein suggested that it was membrane bound and contained extracellular, transmembrane, and cytoplasmic domains." In fact, transfection of MGF cDNA into either COS-7 cells or an SI/Sld-l stromal cell line resulted in the expression of a membrane-bound, biologically active form of MGF when the transfected cells were cocultured with cells responsive to purified soluble MGF.I5 Thus, MGF may be active in a local setting within the microenvironment and its action manifest through cell-cell contact and interaction. These data and other observations'S indicate that the primary hematopoietic target cells for MGF are primitive precursor cells, particularly those with erythroid differentiation potential (BFU-E and CFU-GEMM). Later phenotype cells, such as those responsive to the lineage-specific regulators M-CSF and G-CSF, appear to be considerably less or nonresponsive to the actions of MGF than their predecessors in the hematopoietic hierarchy. The profound effect of MGF on in vitro erythropoiesis is particularly interesting in view of the defect of this lineage in S1 and W mice. 26 The observed increase in the size of normal CFU-GEMM and BFU-E colonies stimulated by MGF plus Epo and CFU-GM colonies stimulated by GM-CSF or G-CSF plus MGF suggests that MGF might serve to promote renewal and expansion of responsive progenitor cells within individual colonies. Serial replating studies of CFU-GEMM, BFU-E, and CFU-GM will be required to address this issue. It is tempting to speculate that the nature of the severe anemia of S1 and W mutant micez6 results from an For personal use only. on November 10, 2017. by guest www.bloodjournal.org From inability to expand the Epo-responsive intermediate progenitor cell pools due to either absence or reduction of the ligand (MGF) or the receptor for this ligand (c-kit). Such a hypothesis is consistent with the apparent refractoriness of these mutant mice to Epo therapyz6 and the partially corrective effects of pharmacologic dosages of SCF on sl/sld mice." Preclinical studies are needed to assess the potential of the c-kit ligand(s) (MGF, SCF, KL) for application to disease and treatment-related hematopoietically suppressedstates.
